Literature DB >> 27587467

Complementing T-cell Function: An Inhibitory Role of the Complement System in T-cell-Mediated Antitumor Immunity.

Weiyi Peng1, Jodi A McKenzie1, Patrick Hwu2.   

Abstract

New data from Wang and colleagues show that complement C3 suppresses the function of CD8(+) tumor-infiltrating T cells by inhibiting IL10 production, and targeting the complement receptors C3aR and C5aR enhances the antitumor activity of immune checkpoint blockade. Their results not only define a new role of complement receptors as T-cell coinhibitory receptors, but also are useful in the development of novel strategies to improve the effectiveness of cancer immunotherapy. Cancer Discov; 6(9); 953-5. ©2016 AACR.See related article by Wang et al., p. 1022. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27587467      PMCID: PMC6069599          DOI: 10.1158/2159-8290.CD-16-0698

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  10 in total

1.  Interleukin-10 ablation promotes tumor development, growth, and metastasis.

Authors:  Takashi Tanikawa; Cailin Moira Wilke; Ilona Kryczek; Grace Y Chen; John Kao; Gabriel Núñez; Weiping Zou
Journal:  Cancer Res       Date:  2011-11-28       Impact factor: 12.701

Review 2.  Complement regulation of T cell immunity.

Authors:  Wing-hong Kwan; William van der Touw; Peter S Heeger
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

3.  Highly activated cytotoxic CD8 T cells express protective IL-10 at the peak of coronavirus-induced encephalitis.

Authors:  Kathryn Trandem; Jingxian Zhao; Erica Fleming; Stanley Perlman
Journal:  J Immunol       Date:  2011-02-11       Impact factor: 5.422

4.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

Review 5.  Innate and adaptive immune cells in the tumor microenvironment.

Authors:  Thomas F Gajewski; Hans Schreiber; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2013-10       Impact factor: 25.606

Review 6.  Molecular mechanisms of T cell co-stimulation and co-inhibition.

Authors:  Lieping Chen; Dallas B Flies
Journal:  Nat Rev Immunol       Date:  2013-03-08       Impact factor: 53.106

Review 7.  Complement modulation of T cell immune responses during homeostasis and disease.

Authors:  Elizabeth V Clarke; Andrea J Tenner
Journal:  J Leukoc Biol       Date:  2014-09-10       Impact factor: 4.962

8.  Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice.

Authors:  R M Berman; T Suzuki; H Tahara; P D Robbins; S K Narula; M T Lotze
Journal:  J Immunol       Date:  1996-07-01       Impact factor: 5.422

9.  Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression.

Authors:  Yu Wang; Sheng-Nan Sun; Qing Liu; Yang-Yang Yu; Jian Guo; Kun Wang; Bao-Cai Xing; Qing-Feng Zheng; Michael J Campa; Edward F Patz; Shi-You Li; You-Wen He
Journal:  Cancer Discov       Date:  2016-06-13       Impact factor: 39.397

Review 10.  The role of complement in tumor growth.

Authors:  Ruben Pio; Leticia Corrales; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

  10 in total
  4 in total

1.  Investigating Cellular Trajectories in the Severity of COVID-19 and Their Transcriptional Programs Using Machine Learning Approaches.

Authors:  Hyun-Hwan Jeong; Johnathan Jia; Yulin Dai; Lukas M Simon; Zhongming Zhao
Journal:  Genes (Basel)       Date:  2021-04-24       Impact factor: 4.096

2.  High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status.

Authors:  Kim E Kortekaas; Saskia J Santegoets; Ziena Abdulrahman; Vanessa J van Ham; Marij van der Tol; Ilina Ehsan; Helena C van Doorn; Tjalling Bosse; Mariëtte I E van Poelgeest; Sjoerd H van der Burg
Journal:  J Immunother Cancer       Date:  2019-09-03       Impact factor: 13.751

Review 3.  A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy.

Authors:  Yu Fujiwara; Arjun Mittra; Abdul Rafeh Naqash; Naoko Takebe
Journal:  Cancer Drug Resist       Date:  2020-06-18

Review 4.  The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy.

Authors:  Yu Wang; Hui Zhang; You-Wen He
Journal:  Front Immunol       Date:  2019-07-19       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.